Parkinson Disease
📧 Sign up to get email alerts when something new happens for Parkinson Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-01-02FDA Approved: RASAGILINE — Supplemental Application (Alvogen, Inc.)
The FDA approved Alvogen's supplemental application for Rasagiline (generic) under an ANDA, enabling a generic Rasagiline tablet for Parkins…
-
FDA approval · 2019-12-30FDA Approved: CARBIDOPA, LEVODOPA, AND ENTACAPONE — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for the Carbidopa/Levodopa/Entacapone combination from Sandoz Inc.
-
FDA approval · 2019-12-17FDA Approved: CARBIDOPA AND LEVODOPA — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application to the NDA for Carbidopa and Levodopa from Zydus Pharmaceuticals USA Inc., approving changes under t…
-
FDA approval · 2019-12-13FDA Approved: BROMOCRIPTINE MESYLATE — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a Supplemental Application for Bromocriptine Mesylate by ANI Pharmaceuticals, Inc. The provided excerpt does not specify a new …
-
CLINICAL_TRIALS withdrawal · 2019-12-10Clinical Trial Update: A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations [Phase 3]
A Phase 3 trial evaluating ND0612 infusion as an adjunct to levodopa in Parkinson's disease has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-12-05FDA Approved: DUOPA — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for DUOPA (carbidopa and levodopa) submitted by AbbVie.
-
CLINICAL_TRIALS trial_result · 2019-12-02Clinical Trial Update: An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients [Phase 1]
Phase 1 exploratory study assessing safety, tolerability, and pharmacokinetics of ascending doses of Lu AE04621 in Parkinson disease patient…
-
FDA approval · 2019-11-25FDA Approved: XADAGO — Supplemental Application (MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc.)
The FDA approved a supplemental application for XADAGO (safinamide mesylate) from MDD US Operations LLC, a subsidiary of Supernus Pharmaceut…
-
FDA approval · 2019-11-21FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA supplemental approval granted to Torrent Pharmaceuticals Limited for pramipexole dihydrochloride, a generic product, enabling its market…
-
FDA approval · 2019-11-21FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for Pramipexole dihydrochloride from Macleods Pharmaceuticals Limited.
-
CLINICAL_TRIALS trial_result · 2019-11-21Clinical Trial Update: Telephone-linked Home-based Exercise Training in PD [NA]
A completed clinical trial evaluating telephone-linked home-based exercise training for Parkinson's disease; results posted in 2019.
-
FDA approval · 2019-11-15FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental ANDA for pramipexole dihydrochloride from Alembic Pharmaceuticals Limited. The product is a generic treatment op…
-
CLINICAL_TRIALS trial_result · 2019-11-14Clinical Trial Update: Effects of Cholinergic Augmentation on Measures of Balance and Gait [Phase 2]
Phase 2 clinical trial assessing the effects of cholinergic augmentation on balance and gait in Parkinson's disease; results posted after co…
-
CLINICAL_TRIALS trial_result · 2019-11-13Clinical Trial Update: Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease [Phase 3]
Phase 3 trial of amantadine for gait dysfunction and freezing in Parkinson's disease was terminated with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-11-06Clinical Trial Update: Pilot Trial of Transnasal Nicotine in Parkinson Disease [Phase 2]
A Phase 2 pilot trial evaluated transnasal nicotine in Parkinson disease and has completed.
-
CLINICAL_TRIALS trial_result · 2019-11-06Clinical Trial Update: A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease [Phase 2]
Phase 2 study reporting pharmacokinetics and pharmacodynamics of IPX203 in patients with advanced Parkinson's disease.
-
CLINICAL_TRIALS trial_result · 2019-11-04Clinical Trial Update: Neural and Kinematic Features of Freezing of Gait for Adaptive Neurostimulation [NA]
Clinical trial investigating neural and kinematic features for adaptive neurostimulation in Parkinson disease; study completed with results …
-
CLINICAL_TRIALS trial_result · 2019-10-31Clinical Trial Update: Effects of Combined rTMS and Treadmill Training in People With Parkinson's Disease [NA]
Clinical trial completed assessing the combined effects of repetitive transcranial magnetic stimulation (rTMS) and treadmill training in Par…
-
CLINICAL_TRIALS research · 2019-10-31Clinical Trial Update: Video Based Mindfulness Based Stress Reduction [NA]
A completed clinical trial evaluating video-based mindfulness-based stress reduction for Parkinson's disease with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-10-29Clinical Trial Update: Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease [Phase 2]
Phase 2 trial comparing IPX054 to immediate-release carbidopa-levodopa in Parkinson's disease has completed.
-
CLINICAL_TRIALS trial_result · 2019-10-29Clinical Trial Update: Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease [Phase 2]
Phase 2 trial comparing IPX054 with immediate-release and controlled-release carbidopa-levodopa in Parkinson's disease completed.
-
CLINICAL_TRIALS trial_result · 2019-10-29Clinical Trial Update: Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH) [Phase 2]
Phase 2 trial evaluating L-Dihydroxyphenylserine (L-DOPS) for reducing falls in patients with neurogenic orthostatic hypotension, Parkinson …
-
FDA approval · 2019-10-21FDA Approved: CARBIDOPA — Original Application (NorthStar Rx LLC)
FDA approved the original ANDA for a generic carbidopa product from NorthStar Rx LLC.
-
FDA approval · 2019-10-10FDA Approved: FLUORODOPA F18 — Original Application (THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH)
FDA approved Fluorodopa F18 (FDOPA F-18) under an original application as a radiopharmaceutical for PET imaging of the brain's dopaminergic …
-
CLINICAL_TRIALS trial_result · 2019-10-04Clinical Trial Update: rTMS on Motor Function of Parkinson's Disease Patients With Different Phenotypes [Phase 2]
Phase 2 clinical trial update evaluating repetitive transcranial magnetic stimulation (rTMS) on motor function in Parkinson's disease patien…